Iradimed (IRMD) EBIT Margin (2013 - 2026)

Iradimed (IRMD) has reported EBIT Margin for 14 consecutive years, with 31.23% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT Margin fell 203.0% year-over-year to 31.23% in Q2 2026; TTM through Jun 2026 was 31.92%, a 125.0% increase from a year earlier, with the FY2025 full-year figure at 31.2%, up 121.0% from the prior year.
• EBIT Margin was 31.23% for Q2 2026 at Iradimed, down from 32.93% in the prior quarter.
• Over five years, EBIT Margin peaked at 35.78% in Q3 2023 and troughed at 24.98% in Q1 2022.
• A 5-year average of 30.43% and a median of 31.02% in 2022 frame the typical range for EBIT Margin.
• Across the five-year window, EBIT Margin surged 1395 bps in 2022 and slumped 419 bps in 2024, its largest moves.
• Over 5 years, EBIT Margin stood at 28.62% in 2022, then grew by 3 bps to 29.57% in 2023, then climbed by 1 bps to 29.92% in 2024, then rose by 4 bps to 31.26% in 2025, then slipped by 0 bps to 31.23% in 2026.
• The last three EBIT Margin figures came in at 31.23% (Q2 2026), 32.93% (Q1 2026), and 31.26% (Q4 2025), per Business Quant data.